{rfName}
Es

Indexed in

Citations

30

Altmetrics

Analysis of institutional authors

Miravitlles, MarcAuthorHuerta, AliciaAuthor

Share

June 7, 2021
Publications
>
Article
No

Estimation of the Clinical and Economic Impact of an Improvement in Adherence Based on the Use of Once-Daily Single-Inhaler Triple Therapy in Patients with COPD

Publicated to: International Journal Of Chronic Obstructive Pulmonary Disease. 15 1643-1654 - 2020-01-01 15(), DOI: 10.2147/COPD.S253567

Authors:

Miravitlles, Marc; Marin, Alicia; Huerta, Alicia; Carcedo, David; Villacampa, Alba; Puig-Junoy, Jaume;
[+]

Affiliations

‎ Ciber Enfermedades Resp CIBERES, Barcelona, Spain - Author
‎ GlaxoSmithKline SA, Market Access Dept, Madrid, Spain - Author
‎ Hosp Badalona Germans Trias & Pujol, Pneumol Dept, Badalona, Spain - Author
‎ Hosp Univ Vall dHebron, Vall dHebron Inst Recerca VHIR, Pneumol Dept, Vall dHebron Hosp Campus, Barcelona, Spain - Author
‎ Hygeia Consulting SL, Madrid, Spain - Author
‎ Univ Pompeu Fabra BSM UPF, Barcelona Sch Management, Barcelona, Spain - Author
See more

Abstract

Background: Adherence to treatment is key to achieve desired outcomes. In COPD, adherence is generally suboptimal and is impaired by treatment complexity. Objective: To estimate the clinical and economic impact of an improvement in treatment adherence due to an increased use of once-daily single-inhaler triple therapy (SITT) in patients with COPD. Patients and Methods: A 7-state Markov model with monthly cycles was developed. Patients with moderate-to-very severe COPD, for whom triple therapy is indicated, were included. Outcomes and costs were estimated and compared for two scenarios: current distribution of adherent patients treated with multiple inhaler triple therapies (MITT) vs a potential scenario where patients shifted to once-daily SITT. In the potential scenario, adherence improvement due to once-daily SITT attributes was estimated. Costing was based on the Spanish National Health System (NHS) perspective ((sic)2019). A 3-year time horizon was defined considering a 3% discount rate for both costs and outcomes. Results: A target population of 185,111 patients with moderate-to-very severe COPD currently treated with MITT was estimated. A 20% increase in the use of once-daily SITT in the potential scenario raised adherence up to 52%. This resulted in 6835 exacerbations and 532 deaths avoided, with 775 LYs and 594 QALYs gained. Total savings reached (sic)7,082,105. Exacerbation reduction accounted for 61.8% ((sic)4,378,201) of savings. Conclusion: Increasing the use of once-daily SITT in patients with moderate-to-very severe COPD treated with triple therapy would be associated with an improvement in adherence, a reduction of exacerbations and deaths, and cost savings for the Spanish NHS.
[+]

Keywords

adherencecopdeconomic evaluationAdherenceAsthmaCopdCost-effectivenessEconomic evaluationGuidelinesHealthcareManagementMedication adherenceNonadherenceObstructive pulmonary-diseasePrevalenceSpainTiotropium

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal International Journal of Chronic Obstructive Pulmonary Disease due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2020, it was in position , thus managing to position itself as a Q1 (Primer Cuartil), in the category Health Policy. Notably, the journal is positioned above the 90th percentile.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2026-04-05:

  • WoS: 7
[+]

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2026-04-05:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 34.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 34 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 5.
  • The number of mentions on the social network X (formerly Twitter): 2 (Altmetric).
[+]

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Miravitlles Fernández, Marc) .

[+]

Awards linked to the item

This study was funded by GlaxoSmithKline plc. (study number: HO-18-19453). Trademarks are owned by or licensed to their respective owners (the GlaxoSmithKline group of companies or AstraZeneca UK Ltd; Boehringer Ingelheim Ltd; Chiesi Ltd; or Novartis Pharmaceuticals UK Ltd). The abstract of this paper was presented at the European Respiratory Society International Congress 2019 name Clinical and economic impact of an improvement in adherence based on specific attributes of single-inhaler triple therapies in COPD patients as a poster presentation with interim findings. The poster's abstract was published in the European Respiratory Journal 2019 Vol 54 Issue suppl 63: PA4194; DOI: 10.1183/13993003.congress-2019.PA4194. Available at: https://erj.ersjournals.com/con tent/54/suppl_63/PA4194.
[+]